# 📉 Hypomagnesemia

## 🚨 EMERGENCY RECOGNITION: Hypomagnesemia

1 **Clinical Suspicion:** Tetany, seizures, or torsades de pointes with normal Ca/K levels 2 **High-Risk Patients:** Chronic alcoholism, diuretics, PPI use, malabsorption 3 **Associated Deficiencies:** Check K, Ca, PO4 - often concurrent (60% hypokalemic) 4 **Treatment Priority:** Must correct Mg FIRST - K refractory until Mg repleted

## 📊 Definition and Clinical Significance

### Hypomagnesemia Definition

- **Serum Magnesium:** \<1.8 mg/dL (0.75 mmol/L)
- **Mild:** 1.2-1.8 mg/dL (0.5-0.75 mmol/L)
- **Moderate:** 0.8-1.2 mg/dL (0.35-0.5 mmol/L)
- **Severe:** \<0.8 mg/dL (\<0.35 mmol/L)
- **Critical Insight:** Normal serum levels don't exclude total body depletion
- **Prevalence:** 2-15% hospitalized, up to 65% ICU patients

## 🎯 Causes of Hypomagnesemia

| Category | Specific Causes | Key Clinical Features | Mechanism |
|----|----|----|----|
| **Nutritional/GI** | Chronic alcohol use disorder | Multiple nutrient deficiencies, withdrawal risk | ↓Absorption, ↑losses, poor intake |
|  | Malabsorption syndromes | Diarrhea, weight loss, steatorrhea | ↓Intestinal absorption |
|  | Bariatric surgery (RYGB) | Post-surgical, rapid weight loss | ↓Absorptive surface area |
| **Renal Losses** | Loop diuretics | Dose-dependent, concurrent hypokalemia | ↓TAL reabsorption |
|  | Proton pump inhibitors | Long-term use (\>1 year) | ↓TRPM6/TRPM7 channels |
|  | Aminoglycosides | Duration-dependent nephrotoxicity | Tubular toxicity |
| **Endocrine** | Diabetes mellitus | Poor glycemic control, osmotic diuresis | ↑Renal losses |
|  | Primary aldosteronism | Hypertension, concurrent hypokalemia | ↑Distal tubule flow |
| **Genetic** | Gitelman syndrome | Hypocalciuria, hypokalemia | NCCT mutations |

## 🔍 Clinical Manifestations

### Neuromuscular Manifestations

- **Early signs:** Fatigue, weakness, irritability
- **Progressive:** Muscle cramps, fasciculations
- **Chvostek/Trousseau signs:** May be positive
- **Severe:** Tetany, seizures, altered mental status
- **Key:** Symptoms usually absent until \<1.2 mg/dL

### Cardiovascular Complications

- **Arrhythmias:** Atrial and ventricular
- **Life-threatening:** Torsades de pointes
- **Enhanced digitalis toxicity:** ↑Na+ cellular accumulation
- **Vascular effects:** Coronary spasm, hypertension
- **ECG changes:** QT prolongation, U waves

### Metabolic Consequences

- **Hypokalemia:** 60% of patients concurrent
- **Hypocalcemia:** PTH resistance/↓secretion
- **Hypophosphatemia:** Impaired PTH action
- **Vitamin D metabolism:** ↓1α-hydroxylase activity
- **Insulin resistance:** ↓Glucose tolerance

### 🧮 Hypomagnesemia Risk and Replacement Calculator

Serum Mg Level (mg/dL): 1.2 Body Weight (kg): 70 Concurrent hypokalemia\
Malabsorption/GI losses\
Ongoing losses (diuretics, etc.)\
Chronic alcohol use disorder **Replacement Protocol:** Enter values to calculate dosing

## 🔬 Diagnostic Workup

### Initial Laboratory Assessment

- **Serum magnesium (fasting):** \<1.8 mg/dL diagnostic
- **Ionized magnesium:** More accurate but limited availability
- **Concurrent electrolytes:** K, Ca, PO4, albumin
- **Intact PTH:** Suppressed in severe deficiency
- **25(OH)D level:** Impaired activation

### Determine Etiology

- **24-hour urine Mg:** \<120 mg/day in deficiency
- **Fractional excretion:** \>2% suggests renal wasting
- **Medication review:** Diuretics, PPIs, antibiotics
- **GI assessment:** Diarrhea, malabsorption history

### Specialized Testing

- **Mg tolerance test:** Gold standard for body stores
- **Genetic testing:** Suspected inherited disorders
- **Alcohol use screening:** CAGE, quantity assessment
- **Nutritional evaluation:** Comprehensive assessment

### 📐 Fractional Excretion of Magnesium (FEMg)

**Formula:** FEMg = (UMg × SCr) / (0.7 × SMg × UCr) × 100

- **Normal response to deficiency:** \<2% (renal conservation)
- **Renal wasting:** \>2% despite hypomagnesemia
- **Clinical utility:** Distinguish renal vs. extrarenal losses

### 🧪 Ionized Magnesium Testing

- **Normal range:** 0.45-0.60 mmol/L
- **Advantages:** Not affected by protein binding
- **Clinical utility:** Better correlation with intracellular stores
- **Limitations:** Limited availability, expensive
- **Consider when:** Normal total Mg with strong clinical suspicion
- **Research evidence:** May detect deficiency earlier than total Mg

## 💊 Treatment Strategies

### Acute Severe Hypomagnesemia (\<1.0 mg/dL)

1 **IV Loading Dose:** 1-2 grams (4-8 mmol) MgSO4 in 50-100 mL NS over 1-2 hours 2 **Continuous Infusion:** 6 grams (24 mmol) MgSO4 in 1000 mL NS over 24 hours 3 **Monitoring:** Serum Mg every 6-8 hours, check DTRs, renal function 4 **Concurrent K replacement:** Required for successful K repletion

### Oral Magnesium Supplementation

- **Preferred forms:** Chloride, citrate, gluconate, glycinate
- **Highly recommended:** Magnesium chloride (25% elemental, excellent absorption)
- **Avoid:** Magnesium oxide (poor absorption, diarrhea)
- **Dosing:** 400-800 mg daily elemental Mg, divided doses
- **Duration:** Weeks to months depending on etiology
- **Side effects:** Diarrhea (dose-limiting, less with chloride form)

### Chronic Parenteral Therapy

- **Indications:** Malabsorption, ongoing losses
- **Dosing:** 2-4 grams MgSO4 weekly or twice-weekly
- **Administration:** Outpatient infusion centers
- **Monitoring:** Monthly serum levels, clinical symptoms

### Treatment of Underlying Conditions

- **Medication review:** Discontinue/modify offending agents
- **Alcohol cessation:** Comprehensive addiction treatment
- **GI disorders:** Specific therapy for malabsorption
- **Endocrine disorders:** Hormone replacement/suppression

## 💊 Oral Magnesium Formulations

| Formulation | Elemental Mg Content | Bioavailability | GI Tolerance | Clinical Notes |
|----|----|----|----|----|
| **Magnesium Oxide** | 60% | 4% (Poor) | Poor - Diarrhea | Avoid - despite high Mg content |
| **Magnesium Citrate** | 16% | 25-30% (Good) | Good | Preferred oral form |
| **Magnesium Gluconate** | 5.4% | 25-30% (Good) | Excellent | Well tolerated, lower Mg per pill |
| **Magnesium Glycinate** | 14% | 35-40% (Excellent) | Excellent | Chelated form, optimal absorption |
| **Magnesium Lactate** | 12% | 25-30% (Good) | Good | Alternative to citrate |
| **Magnesium Chloride** | 25% | 30-35% (Excellent) | Very Good | Highly bioavailable, well-tolerated |

## ⚠️ Special Clinical Considerations

### PPI-Induced Hypomagnesemia

- **Mechanism:** ↓TRPM6/TRPM7 intestinal channels
- **Time course:** Usually \>1 year of therapy
- **High risk:** Concurrent thiazides, elderly
- **Management:** PPI discontinuation often required
- **Alternatives:** H2 blockers don't affect Mg absorption

### Alcohol Use Disorder

- **Multiple mechanisms:** ↓Intake, ↓absorption, ↑losses
- **Withdrawal risk:** ↑Seizure susceptibility
- **Nutritional rehab:** Thiamine, folate, B12 deficiencies
- **Higher requirements:** During detoxification
- **Comprehensive care:** Addiction medicine referral

### Diuretic-Induced Deficiency

- **Loop diuretics:** Greatest Mg wasting (TAL)
- **Thiazides:** Gitelman syndrome phenocopy
- **Dose-dependent:** \>80 mg furosemide daily high risk
- **Prevention:** K-sparing diuretics may help
- **Monitoring:** Baseline, 1-2 weeks, then q3-6 months

## 🔄 Critical Electrolyte Interactions

### Magnesium-Potassium Relationship

- **Physiologic interdependence:** Mg deficiency impairs renal K conservation
- **Clinical significance:** 60% of hypomagnesemic patients have hypokalemia
- **Treatment priority:** Must correct Mg FIRST - K refractory otherwise
- **Mechanism:** ↓Na-K-ATPase activity, ↑K channel activity
- **Dosing:** Simultaneous replacement more effective than sequential

### Magnesium-Calcium-PTH Axis

- **PTH synthesis:** Mg required for hormone production
- **PTH secretion:** Severe Mg deficiency (\<1.0 mg/dL) suppresses PTH
- **PTH resistance:** ↓Target organ responsiveness in Mg deficiency
- **Vitamin D metabolism:** Mg cofactor for 1α-hydroxylase
- **Clinical result:** Hypocalcemia refractory to Ca replacement until Mg corrected

## 📊 Monitoring and Follow-up

### Acute Treatment Monitoring

- **Serum Mg:** Every 6-8 hours during IV replacement
- **Renal function:** Creatinine, avoid overload
- **Deep tendon reflexes:** Clinical improvement marker
- **Cardiac monitoring:** If arrhythmias present

### Chronic Management

- **Target level:** \>1.8 mg/dL, ideally 2.0-2.4 mg/dL
- **Follow-up frequency:** Weekly initially, then monthly
- **Symptom assessment:** Muscle cramps, weakness resolution
- **Concurrent electrolytes:** K, Ca, PO4 normalization

## 🎯 Key Learning Points

- **Recognition:** Consider in alcohol use disorder, chronic diuretics, PPI therapy, malabsorption
- **Clinical Clues:** Refractory hypokalemia, unexplained tetany, torsades de pointes
- **Diagnostic Limitation:** Normal serum Mg doesn't exclude total body depletion
- **Treatment Priority:** Must correct magnesium BEFORE potassium will respond
- **Oral Forms:** Chloride, citrate, gluconate, glycinate preferred; avoid oxide
- **IV Replacement:** 1-2g loading dose, then 6g/24h for severe deficiency
- **PPI Association:** Long-term PPI use can cause refractory hypomagnesemia
- **Electrolyte Interactions:** Affects K, Ca, PO4 - comprehensive replacement needed
- **Prevention:** Monitor high-risk patients, consider prophylactic supplementation


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/magnesium/hypomagnesemia.html) · Markdown synchronized October 3, 2026.


## Day 1 mechanism infographics — October 21, 2026

### Why potassium may not stay corrected

Low magnesium can permit ongoing renal potassium loss

[Full infographic, text companion and sources](https://urinenephrology.org/visual-reference/day1-magnesium-potassium.html)

Intracellular magnesium inhibits ROMK on the urine-facing membrane of distal-nephron cells. Lower intracellular magnesium reduces this restraint. Distal sodium delivery and ENaC activity help provide the electrical driving force for potassium secretion from cell to urine.